No Single SGLT-2 Inhibitor is Definitively Most Associated with UTI
Based on the highest quality evidence, large clinical trials have shown no difference in the rates of urinary tract infections or serious urinary tract infections between SGLT-2 inhibitors and placebo as a class 1. However, when examining individual agents, dapagliflozin at 10 mg daily shows the most consistent signal for increased UTI risk 2.
Evidence-Based Risk Assessment by Agent
Dapagliflozin
- Highest UTI signal among SGLT-2 inhibitors in drug-specific meta-analyses 2
- Dapagliflozin 10 mg daily associated with significantly increased UTI risk versus placebo (RR 1.33,95% CI 1.10-1.61) 2
- High-dose, long-term treatment (>24 weeks) shows OR 1.27 for UTI compared to controls 3
- However, paradoxically shows lowest risk of fungal infections (ROR 0.874) 4
Empagliflozin
- Lowest UTI risk profile among SGLT-2 inhibitors 4
- ROR 0.928 (95% CI 0.858-1.005) for UTI risk 4
- No increased amputation risk observed in EMPA-REG OUTCOME post-hoc analyses 1
Canagliflozin
- Mixed evidence with no clear UTI signal in major trials 2
- More concerning for other safety issues: black box warning for lower limb amputation (6.3 vs 3.4 per 1,000 patient-years) 1
Critical Context from Guidelines
The 2018 ACC Expert Consensus emphasizes that despite postmarketing reports of pyelonephritis and urosepsis, large clinical trials demonstrate no difference in UTI rates between SGLT-2 inhibitors and placebo 1. This represents a crucial distinction between:
- Spontaneous postmarketing surveillance (subject to reporting bias)
- Rigorous randomized controlled trial data (more reliable)
The most recent 2025 guidelines confirm that genitourinary infections occur at 2-10% rates across all SGLT-2 inhibitors, are usually dose-dependent, and UTIs are more common in females 5.
High-Risk Populations Requiring Vigilance
Regardless of specific agent, monitor closely in patients with 5, 6:
- Female sex (significantly higher UTI prevalence: 68% vs 32% in males) 7
- Older adults (age-dependent increased risk)
- Prior history of genitourinary infections
- Uncontrolled hyperglycemia
- Uncircumcised males
- Recurrent or severe UTI history 6
Important Clinical Distinction
Genital mycotic infections (candida vaginitis, balanitis) are definitively increased with all SGLT-2 inhibitors (RR 3.37-3.89) 1, 2, but these are:
- Not usually serious
- Resolve with brief antifungal courses
- Rarely recur 1
Practical Recommendation
If UTI risk is a primary concern, empagliflozin appears to have the most favorable safety profile 4. However, do not withhold SGLT-2 inhibitors based solely on UTI concerns given their proven mortality and morbidity benefits in cardiovascular disease, heart failure, and CKD 5, 8, 9. The cardiovascular and renal protective effects far outweigh the modest infection risks in appropriately selected patients.
For patients with recurrent UTIs, consider empagliflozin over dapagliflozin, provide hygienic counseling, and monitor closely during the first 90 days 6, 8.